Sat, Aug 23, 2014, 11:20 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • havenger2001 havenger2001 May 23, 2012 8:46 PM Flag

    Keep An Eye Out For Lilly !

    Lilly, I'll regrettably part with my shares @$53/shr. Come get them!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I take 'crazy eights' - $88 that is to Lilly! All others, give it up for $55

      :-------) (Wonder if that why 'DAN' the man smile so big?)

      • 1 Reply to bydureon_q_week
      • And the winner is TAKEDA !
        (they've finished their "look @ the books"
        evaluation, which I'm sure they paid AMLN
        1/4 $M to do so )

        Their offer will be $37ish - it will be rejected & countered for a final price of $42.

        There you go - remember who told you first.
        And the deal is annouced soon & closed by yr end.

        Takeda California is Takeda's Center of Excellence and Innovation for Structure-Based Drug Discovery and Protein Therapeutics. The company combines cutting-edge protein x-ray crystallography, small molecule, antibody, and antibody drug-conjugate capabilities to efficiently generate potential new medicines for treating cancer, inflammatory diseases and metabolic diseases. Multiple potential new drugs invented at Takeda California are in clinical trials evaluation including NESINA® (generic name Alogliptin) which was approved for treating patients with type II diabetes in Japan in 2010.

        Takeda California is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a 230-year heritage. Together with its worldwide partners in science, Takeda California is committed to strive toward better health for patients through leading innovation in medicine.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.